Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) emerged in late 2019 and resulted in a devastating pandemic. Although the first approved vaccines were already administered by the end of 2020, worldwide vaccine availability is still limited. Moreover, immune escape variants of the virus are emerging against which the current vaccines may confer only limited protection. Further, existing antivirals and treatment options against COVID-19 show only limited efficacy. Influenza A virus (IAV) defective interfering particles (DIPs) were previously proposed not only for antiviral treatment of the influenza disease but also for pan-specific treatment of interferon (IFN)-sensitive respiratory virus infections. To investigate the applicability of IAV DIPs as an antiviral for the treatment of COVID-19, we conducted in vitro co-infection experiments with cell culture-derived DIPs and the IFN-sensitive SARS-CoV-2 in human lung cells. We show that treatment with IAV DIPs leads to complete abrogation of SARS-CoV-2 replication. Moreover, this inhibitory effect was dependent on janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling. Further, our results suggest boosting of IFN-induced antiviral activity by IAV DIPs as a major contributor in suppressing SARS-CoV-2 replication. Thus, we propose IAV DIPs as an effective antiviral agent for treatment of COVID-19, and potentially also for suppressing the replication of new variants of SARS-CoV-2.
【저자키워드】 COVID-19, SARS-CoV-2, Antiviral, Innate immunity, influenza A virus, defective interfering particles, OP7, DI244, 【초록키워드】 Treatment, coronavirus disease, severe acute respiratory syndrome coronavirus 2, Coronavirus disease 2019, Efficacy, Vaccine, coronavirus, pandemic, Antiviral, Influenza, Transcription, variant, influenza A virus, interferon, Antiviral treatment, in vitro, antiviral activity, severe acute respiratory syndrome Coronavirus, virus, influenza A, Particle, Replication, Immune escape, Cell culture, Co-infection, experiment, respiratory, antiviral agent, disease, SARS-CoV-2 replication, defective interfering particles, virus infections, Respiratory virus infections, JAK/STAT, Signaling, Janus kinase, STAT, leads, acute respiratory syndrome, treatment of COVID-19, acute respiratory syndrome coronavirus, janus, inhibitory effect, vaccine availability, human lung cells, applicability, abrogation, variants of SARS-CoV-2, Administered, Complete, IAV, effective, Cell, approved, conducted, dependent on, DIP, 【제목키워드】 influenza A virus, antiviral activity, Particle, activity, defective interfering particles, Stimulation, Innate,